{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:58:16Z","timestamp":1795111096886,"version":"4.10.3"},"reference-count":158,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001704"],"award-info":[{"award-number":["82001704"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Sailing Program","award":["20YF1427100"],"award-info":[{"award-number":["20YF1427100"]}]},{"name":"Shanghai Science and Technology Innovation Action","award":["20Y11911500"],"award-info":[{"award-number":["20Y11911500"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult-onset Still\u2019s disease (AOSD) is a rare, but characteristic non-familial, multi-genic systemic auto-inflammatory disorder, characterized by high spiking fever, salmon-like evanescent skin rash, polyarthritis, sore throat, hyperferritinemia and leucocytosis. The hallmark of AOSD is a cytokine storm triggered by dysregulation of inflammation. Nowadays, with advances in anti-cytokine biologic agents, the treatment of AOSD is no longer limited to NSAIDs, glucocorticoids or conventional synthetic DMARDs. In this review, we focussed on the roles of these cytokines in the pathogenesis of AOSD and summarized the current and emerging biological therapy.<\/jats:p>","DOI":"10.1093\/rheumatology\/keab485","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T19:22:06Z","timestamp":1623439326000},"page":"3986-4000","source":"Crossref","is-referenced-by-count":38,"title":["Current and emerging biological therapy in adult-onset Still\u2019s disease"],"prefix":"10.1093","volume":"60","author":[{"given":"Yuning","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"},{"name":"Department of Rheumatology and Immunology, The Fourth Affiliated Hospital of Nantong University, The First People\u2019s Hospital of Yancheng, Yancheng, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchao","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengde","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4825-5227","authenticated-orcid":false,"given":"Qiongyi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,12]]},"reference":[{"key":"2021090119430767900_keab485-B1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.54.7.587","article-title":"Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France","volume":"54","author":"Magadur-Joly","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2188\/jea.7.221","article-title":"Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan","volume":"7","author":"Wakai","year":"1997","journal-title":"J Epidemiol"},{"key":"2021090119430767900_keab485-B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/03009740510026616","article-title":"Epidemiology and outcome of adult-onset Still's disease in Northern Norway","volume":"35","author":"Evensen","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"2021090119430767900_keab485-B4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2014.01.011","article-title":"Diagnosis and classification of adult Still's disease","volume":"48\u201349","author":"Mahroum","year":"2014","journal-title":"J Autoimmun"},{"key":"2021090119430767900_keab485-B5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still's disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2021090119430767900_keab485-B6","first-page":"47","author":"Still","year":"1897"},{"key":"2021090119430767900_keab485-B7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still's disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still's disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"key":"2021090119430767900_keab485-B9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/art.1780300209","article-title":"Adult-onset Still's disease. Clinical course and outcome","volume":"30","author":"Cush","year":"1987","journal-title":"Arthritis Rheum"},{"key":"2021090119430767900_keab485-B10","doi-asserted-by":"crossref","first-page":"603389","DOI":"10.3389\/fimmu.2020.603389","article-title":"Cytokine storm in coronavirus disease 2019 and adult-onset Still's disease: similarities and differences","volume":"11","author":"Meng","year":"2021","journal-title":"Front Immunol"},{"key":"2021090119430767900_keab485-B11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","article-title":"Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles","volume":"61","author":"Shimizu","year":"2013","journal-title":"Cytokine"},{"key":"2021090119430767900_keab485-B12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/acr.22194","article-title":"Clinical manifestations of adult-onset Still's disease presenting with erosive arthritis: association with low levels of ferritin and Interleukin-18","volume":"66","author":"Ichida","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2021090119430767900_keab485-B13","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology"},{"key":"2021090119430767900_keab485-B14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ncprheum0681","article-title":"Primer: inflammasomes and interleukin 1beta in inflammatory disorders","volume":"4","author":"Church","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2021090119430767900_keab485-B15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res"},{"key":"2021090119430767900_keab485-B16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2021090119430767900_keab485-B17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbspin.2017.05.011","article-title":"New markers for adult-onset Still's disease","volume":"85","author":"Mitrovic","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2021090119430767900_keab485-B18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14737159.2019.1615449","article-title":"The role of damage-associated molecular pattern for pathogenesis and biomarkers in adult-onset Still's disease","volume":"19","author":"Jung","year":"2019","journal-title":"Expert Rev Mol Diagnost"},{"key":"2021090119430767900_keab485-B19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2021090119430767900_keab485-B20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3899\/jrheum.161354","article-title":"Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset Still disease","volume":"44","author":"Hsieh","year":"2017","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-018-1800-z","article-title":"Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease","volume":"21","author":"Hu","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2021090119430767900_keab485-B22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/nri1983","article-title":"Perforin-mediated target-cell death and immune homeostasis","volume":"6","author":"Voskoboinik","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"2021090119430767900_keab485-B23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","article-title":"Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis","volume":"49","author":"Vastert","year":"2010","journal-title":"Rheumatology"},{"key":"2021090119430767900_keab485-B24","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/art.34514","article-title":"Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells","volume":"64","author":"Lee","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021090119430767900_keab485-B25","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.3899\/jrheum.111500","article-title":"Natural killer cell cytolytic function in Korean patients with adult-onset Still's disease","volume":"39","author":"Park","year":"2012","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B26","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3899\/jrheum.181192","article-title":"Characteristics of circulating natural killer cells and their interferon-\u03b3 production in active adult-onset Still disease","volume":"46","author":"Shimojima","year":"2019","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3109\/03008200903461462","article-title":"The associations of circulating CD4+CD25high regulatory T cells and TGF-\u03b2 with disease activity and clinical course in patients with adult-onset Still's disease","volume":"51","author":"Chen","year":"2010","journal-title":"Connect Tissue Res"},{"key":"2021090119430767900_keab485-B28","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/ard.2003.013680","article-title":"Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease","volume":"63","author":"Chen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B29","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/rheumatology\/keq284","article-title":"Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease","volume":"49","author":"Chen","year":"2010","journal-title":"Rheumatology"},{"key":"2021090119430767900_keab485-B30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"Coffman RL TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"2021090119430767900_keab485-B31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"2021090119430767900_keab485-B32","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1007\/s10067-019-04642-x","article-title":"Elevated serum levels of interleukin-10 in adult-onset Still's disease are associated with disease activity","volume":"38","author":"Sun","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2021090119430767900_keab485-B33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13075-018-1555-6","article-title":"Interleukin-37 is increased in adult-onset Still's disease and associated with disease activity","volume":"20","author":"Chi","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021090119430767900_keab485-B34","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.147.11.3815","article-title":"IL-10 inhibits cytokine production by activated macrophages","volume":"147","author":"Fiorentino","year":"1991","journal-title":"J Immunol"},{"key":"2021090119430767900_keab485-B35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1126\/science.aal3535","article-title":"Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages","volume":"356","author":"Ip","year":"2017","journal-title":"Science"},{"key":"2021090119430767900_keab485-B36","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaci.2015.10.018","article-title":"IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration","volume":"137","author":"Kulkarni","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2021090119430767900_keab485-B37","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.1944","article-title":"IL-37 is a fundamental inhibitor of innate immunity","volume":"11","author":"Nold","year":"2010","journal-title":"Nat Immunol"},{"key":"2021090119430767900_keab485-B38","first-page":"doi:10.4238\/gmr.15027616","article-title":"Protective effect of the polarity of macrophages regulated by IL-37 on atherosclerosis","volume":"15","author":"Huang","year":"2016","journal-title":"Genet Mol Res"},{"key":"2021090119430767900_keab485-B39","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.immuni.2014.03.011","article-title":"Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function","volume":"40","author":"Shouval","year":"2014","journal-title":"Immunity"},{"key":"2021090119430767900_keab485-B40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/art.1780241203","article-title":"HLA-Bw35 and prognosis in adult Still's disease","volume":"24","author":"Terkeltaub","year":"1981","journal-title":"Arthritis Rheum"},{"key":"2021090119430767900_keab485-B41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still's disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine"},{"key":"2021090119430767900_keab485-B42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/art.1780290316","article-title":"Adult-onset Still's disease. Disease course and HLA associations","volume":"29","author":"Wouters","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2021090119430767900_keab485-B43","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","article-title":"Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease","volume":"40","author":"Fujii","year":"2001","journal-title":"Rheumatology"},{"key":"2021090119430767900_keab485-B44","first-page":"489","article-title":"Association between HLA-DR B1 and clinical features of adult onset Still's disease in Korea","volume":"21","author":"Joung","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2021090119430767900_keab485-B45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/annrheumdis-2019-215239","article-title":"Both class I and II regions identified as genome-wide significant susceptibility loci for adult-onset Still's disease in Chinese individuals","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B46","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1172\/JCI2629","article-title":"The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis","volume":"102","author":"Fishman","year":"1998","journal-title":"J Clin Investig"},{"key":"2021090119430767900_keab485-B47","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3899\/jrheum.090316","article-title":"Functional association of interleukin 18 gene -607 (C\/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still's disease","volume":"36","author":"Chen","year":"2009","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B48","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4239","article-title":"A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease","volume":"15","author":"Wang","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2021090119430767900_keab485-B49","doi-asserted-by":"crossref","first-page":"e13394","DOI":"10.1097\/MD.0000000000013394","article-title":"Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still's disease","volume":"97","author":"Yashiro","year":"2018","journal-title":"Medicine"},{"key":"2021090119430767900_keab485-B50","first-page":"60","article-title":"MEFV gene mutations and their clinical significance in Korean patients with adult-onset Still's disease","volume":"31","author":"Kim","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2021090119430767900_keab485-B51","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/art.41635","article-title":"Association of leukocyte immunoglobulin-like receptor A3 (LILRA3) with neutrophil activation and its susceptibility in adult-onset Still's disease","volume":"73","author":"Wang","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2021090119430767900_keab485-B52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-00571-1","article-title":"Bridgewood C Immune cartography of macrophage activation syndrome in the COVID-19 era","volume":"17","author":"McGonagle","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2021090119430767900_keab485-B53","first-page":"1058","article-title":"Adult Still's disease: a multicenter survey of Japanese patients","volume":"17","author":"Ohta","year":"1990","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B54","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/ard.47.9.764","article-title":"Adult onset Still's disease and viral infections","volume":"47","author":"Wouters","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/ard.59.6.490c","article-title":"Rubella infection in adult onset Still's disease","volume":"59","author":"Escudero","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0950-3579(05)80283-3","article-title":"Adult-onset Still's disease","volume":"5","author":"van de Putte","year":"1991","journal-title":"Bailliere's Clin Rheumatol"},{"key":"2021090119430767900_keab485-B57","doi-asserted-by":"crossref","first-page":"2071815","DOI":"10.1155\/2016\/2071815","article-title":"Adult onset Still's disease associated with infection and hemophagocytic lymphohistiocytosis","volume":"2016","author":"Agnihotri","year":"2016","journal-title":"Case Rep Med"},{"key":"2021090119430767900_keab485-B58","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.berh.2004.05.004","article-title":"Adult-onset Still's disease","volume":"18","author":"K\u00e1d\u00e1r","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2021090119430767900_keab485-B59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2016.02.010","article-title":"Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: data from a large multicenter cohort","volume":"69","author":"Kalyoncu","year":"2016","journal-title":"J Autoimmun"},{"key":"2021090119430767900_keab485-B60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still's disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2021090119430767900_keab485-B61","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/art.27532","article-title":"Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease","volume":"62","author":"Franchini","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021090119430767900_keab485-B62","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10067-016-3308-8","article-title":"Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients","volume":"35","author":"Sfriso","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2021090119430767900_keab485-B63","first-page":"16634","article-title":"Clinical features and prognosis of adult-onset Still's disease: 75 cases from China","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2021090119430767900_keab485-B64","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"2021090119430767900_keab485-B65","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrrheum.2016.166","article-title":"Interleukin-1 function and role in rheumatic disease","volume":"12","author":"Schett","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2021090119430767900_keab485-B66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1101\/sqb.2013.78.021246","article-title":"IL-1\u03b2 strikingly enhances antigen-driven CD4 and CD8 T-cell responses","volume":"78","author":"Ben-Sasson","year":"2013","journal-title":"Cold Spring Harbor Symp Quant Biol"},{"key":"2021090119430767900_keab485-B67","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fimmu.2013.00182","article-title":"IL-1 and T Helper Immune Responses","volume":"4","author":"Santarlasci","year":"2013","journal-title":"Front Immunol"},{"key":"2021090119430767900_keab485-B68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/TCRM.S155488","article-title":"Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review","volume":"14","author":"Zhou","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"2021090119430767900_keab485-B69","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14712598.2019.1652591","article-title":"Biologics for the treatment of adult-onset still's disease","volume":"19","author":"Yoo","year":"2019","journal-title":"Expert Opinion Biol Ther"},{"key":"2021090119430767900_keab485-B70","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease","volume":"69","author":"Naumann","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B71","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B72","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B73","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/ar3366","article-title":"Moutsopoulos HM Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study","volume":"13","author":"Laskari","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2021090119430767900_keab485-B74","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","article-title":"Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy","volume":"65","author":"Giampietro","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2021090119430767900_keab485-B75","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanju\u00e1n","year":"2015","journal-title":"Medicine"},{"key":"2021090119430767900_keab485-B76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13054-018-2012-2","article-title":"Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review","volume":"22","author":"N\u00e9el","year":"2018","journal-title":"Crit Care"},{"key":"2021090119430767900_keab485-B77","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups","volume":"36","author":"Feist","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2021090119430767900_keab485-B78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fphar.2017.00369","article-title":"Response to Interleukin-1 inhibitors in 140 Italian patients with adult-onset Still's disease: a multicentre retrospective observational study","volume":"8","author":"Colafrancesco","year":"2017","journal-title":"Front Pharmacol"},{"key":"2021090119430767900_keab485-B79","doi-asserted-by":"crossref","first-page":"1759720X2093313","DOI":"10.1177\/1759720X20933133","article-title":"The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still's disease. A systematic review and meta-analysis of observational studies","volume":"12","author":"Ruscitti","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2021090119430767900_keab485-B80","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40265-018-0956-9","article-title":"Adult-onset Still's disease: molecular pathophysiology and therapeutic advances","volume":"78","author":"Sfriso","year":"2018","journal-title":"Drugs"},{"key":"2021090119430767900_keab485-B81","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-015-0047-3","article-title":"Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity","volume":"13","author":"Nirmala","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"2021090119430767900_keab485-B82","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B83","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2125.2011.03958.x","article-title":"Rilonacept and canakinumab","volume":"71","author":"Dubois","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2021090119430767900_keab485-B84","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","article-title":"IL-1 Trap rilonacept in refractory adult onset Still's disease","volume":"71","author":"Petryna","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B85","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard.2005.047621","article-title":"Successful treatment of refractory adult onset Still's disease with rituximab","volume":"65","author":"Ahmadi-Simab","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B86","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4081\/reumatismo.2016.888","article-title":"Successful treatment of refractory adult onset Still's disease with rituximab","volume":"68","author":"Belfeki","year":"2016","journal-title":"Reumatismo"},{"key":"2021090119430767900_keab485-B87","first-page":"1831)","article-title":"Safety and efficacy of IL-1 Trap in resistant adult onset Still's disease: 24 month follow-up of open label treatment and biomarkers of response","volume":"62","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021090119430767900_keab485-B88","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021090119430767900_keab485-B89","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"2021090119430767900_keab485-B90","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","article-title":"The soluble Interleukin 6 receptor: generation and role in inflammation and cancer","volume":"90","author":"Chalaris","year":"2011","journal-title":"Eur J Cell Biol"},{"key":"2021090119430767900_keab485-B91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","article-title":"Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer","volume":"21","author":"Grivennikov","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021090119430767900_keab485-B92","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.V86.4.1243.bloodjournal8641243","article-title":"Interleukin-6 family of cytokines and gp130","volume":"86","author":"Kishimoto","year":"1995","journal-title":"Blood"},{"key":"2021090119430767900_keab485-B93","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"2021090119430767900_keab485-B94","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"2021090119430767900_keab485-B95","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/art.10620","article-title":"Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease","volume":"46","author":"Iwamoto","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021090119430767900_keab485-B96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still's disease","volume":"63","author":"Pu\u00e9chal","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2021090119430767900_keab485-B97","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/s10165-011-0569-6","article-title":"Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan","volume":"22","author":"Suematsu","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2021090119430767900_keab485-B98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still's disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2021090119430767900_keab485-B99","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3899\/jrheum.130881","article-title":"Tocilizumab in adult-onset Still's disease: the Israeli experience","volume":"41","author":"Elkayam","year":"2014","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B100","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.immuni.2015.06.003","article-title":"Proteolytic processing of interleukin-1 family cytokines: variations on a common theme","volume":"42","author":"Afonina","year":"2015","journal-title":"Immunity"},{"key":"2021090119430767900_keab485-B101","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/14397595.2014.899178","article-title":"Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease","volume":"26","author":"Bannai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2021090119430767900_keab485-B102","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B103","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still's disease: a retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2021090119430767900_keab485-B104","first-page":"S64","article-title":"Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases","volume":"34","author":"Song","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2021090119430767900_keab485-B105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10067-012-2105-2","article-title":"Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence","volume":"32","author":"de Boysson","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2021090119430767900_keab485-B106","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00296-010-1631-y","article-title":"Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature","volume":"31","author":"Thonhofer","year":"2011","journal-title":"Rheumatol Int"},{"key":"2021090119430767900_keab485-B107","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10067-011-1917-9","article-title":"Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review","volume":"31","author":"Sakai","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2021090119430767900_keab485-B108","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.reuma.2013.05.004","article-title":"Efficacy of tocilizumab in refractory adult-onset Still's disease; report of 2 cases","volume":"10","author":"Andrade-Ortega","year":"2014","journal-title":"Reumatol Clin"},{"key":"2021090119430767900_keab485-B109","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021090119430767900_keab485-B110","doi-asserted-by":"crossref","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","article-title":"A pilot study on tocilizumab for treating refractory adult-onset Still's disease","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"2021090119430767900_keab485-B111","doi-asserted-by":"crossref","first-page":"5656320","DOI":"10.1155\/2016\/5656320","article-title":"Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still's disease: a case-based review","volume":"2016","author":"Watanabe","year":"2016","journal-title":"Case Rep Med"},{"key":"2021090119430767900_keab485-B112","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10067-010-1418-2","article-title":"Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab","volume":"29","author":"Sumida","year":"2010","journal-title":"Clin Rheumatol"},{"key":"2021090119430767900_keab485-B113","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","article-title":"Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome","volume":"21","author":"Kobayashi","year":"2011","journal-title":"Mod Rheumatol"},{"key":"2021090119430767900_keab485-B114","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/1756-185X.12324","article-title":"A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: targeting IL-6","volume":"17","author":"Kadavath","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"2021090119430767900_keab485-B115","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/kez154","article-title":"Efficacy of sarilumab in adult-onset Still's disease as a corticosteroid-sparing agent","volume":"58","author":"Simeni Njonnou","year":"2019","journal-title":"Rheumatology"},{"issue":"Suppl 3","key":"2021090119430767900_keab485-B116","first-page":"key075.446","article-title":"222\u2003Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab","volume":"57","author":"Emery","year":"2018","journal-title":"Rheumatology"},{"key":"2021090119430767900_keab485-B117","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat Reviews Drug discovery"},{"key":"2021090119430767900_keab485-B118","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"2021090119430767900_keab485-B119","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2021090119430767900_keab485-B120","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B121","first-page":"329","article-title":"Infliximab in the treatment of adult Still's disease refractory to conventional therapy","volume":"19","author":"Cavagna","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 3","key":"2021090119430767900_keab485-B122","first-page":"iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences","volume":"60","author":"Kraetsch","year":"2001","journal-title":"Annals Rheum Dis"},{"key":"2021090119430767900_keab485-B123","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B124","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still's disease","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021090119430767900_keab485-B125","first-page":"733","article-title":"Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report","volume":"23","author":"Benucci","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2021090119430767900_keab485-B126","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/ard.2010.129403","article-title":"Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade","volume":"70","author":"Rech","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imr.12908","article-title":"Therapeutic modulation of inflammasome pathways","volume":"297","author":"Chauhan","year":"2020","journal-title":"Immunol Rev"},{"key":"2021090119430767900_keab485-B128","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/kew300","article-title":"Elevated serum levels of free interleukin-18 in adult-onset Still's disease","volume":"55","author":"Girard","year":"2016","journal-title":"Rheumatology"},{"key":"2021090119430767900_keab485-B129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/03009742.2013.824023","article-title":"Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still's disease","volume":"43","author":"Jung","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2021090119430767900_keab485-B130","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3899\/jrheum.090662","article-title":"Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases","volume":"37","author":"Maruyama","year":"2010","journal-title":"J Rheumatol"},{"key":"2021090119430767900_keab485-B131","first-page":"840","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B132","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1136\/annrheumdis-2018-214496","article-title":"Prolonged treatment with Tadekinig alfa in adult-onset Still's disease","volume":"79","author":"Kiltz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B133","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"2021090119430767900_keab485-B134","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 2","key":"2021090119430767900_keab485-B135","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B136","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B137","doi-asserted-by":"crossref","first-page":"152.3","DOI":"10.1136\/annrheumdis-2012-eular.1965","article-title":"Genovese M 12-Week results of a Phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAJ\/JAK2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis","volume":"71","author":"Keystone","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B138","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/key414","article-title":"Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy","volume":"58","author":"Ladhari","year":"2019","journal-title":"Rheumatology"},{"key":"2021090119430767900_keab485-B139","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.4049\/jimmunol.1001311","article-title":"Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells","volume":"185","author":"Platt","year":"2010","journal-title":"J Immunol"},{"key":"2021090119430767900_keab485-B140","first-page":"265","article-title":"Efficacy of abatacept in a refractory case of adult-onset Still's disease","volume":"28","author":"Quartuccio","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2021090119430767900_keab485-B141","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/RHU.0b013e31822c53ad","article-title":"Kadanoff R Refractory adult-onset still disease successfully treated with abatacept","volume":"17","author":"Ostrowski","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"2021090119430767900_keab485-B142","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200305000-00011","article-title":"The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets","volume":"15","author":"D\u00f6rner","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"2021090119430767900_keab485-B143","first-page":"888","article-title":"Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody","volume":"27","author":"Bartoloni","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2021090119430767900_keab485-B144","first-page":"657","article-title":"Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease","volume":"31","author":"Padilla-Ibarra","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2021090119430767900_keab485-B145","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.V80.6.1565.1565","article-title":"Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins","volume":"80","author":"Yong","year":"1992","journal-title":"Blood"},{"key":"2021090119430767900_keab485-B146","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/cdd.2009.96","article-title":"Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps","volume":"16","author":"Yousefi","year":"2009","journal-title":"Cell Death Differ"},{"key":"2021090119430767900_keab485-B147","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1165\/rcmb.2010-0101OC","article-title":"Granulocyte\/macrophage colony-stimulating factor causes a paradoxical increase in the BH3-only pro-apoptotic protein Bim in human neutrophils","volume":"44","author":"Cowburn","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2021090119430767900_keab485-B148","first-page":"420","article-title":"The expanding world of extracellular traps: not only neutrophils but much more","volume":"3","author":"Goldmann","year":"2012","journal-title":"Front Immunol"},{"key":"2021090119430767900_keab485-B149","doi-asserted-by":"crossref","first-page":"e58598","DOI":"10.1371\/journal.pone.0058598","article-title":"RNA-seq reveals activation of both common and cytokine-specific pathways following neutrophil priming","volume":"8","author":"Wright","year":"2013","journal-title":"PLoS one"},{"key":"2021090119430767900_keab485-B150","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/keaa368","article-title":"Neutrophil-derived lipocalin-2 in adult-onset Still's disease: a novel biomarker of disease activity and liver damage","volume":"60","author":"Jia","year":"2021","journal-title":"Rheumatology"},{"key":"2021090119430767900_keab485-B151","doi-asserted-by":"crossref","first-page":"563335","DOI":"10.3389\/fimmu.2020.563335","article-title":"Circulating neutrophil extracellular traps signature for identifying organ involvement and response to glucocorticoid in adult-onset Still's disease: a machine learning study","volume":"11","author":"Jia","year":"2020","journal-title":". Front Immunol"},{"key":"2021090119430767900_keab485-B152","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1136\/annrheumdis-2014-205234","article-title":"Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis","volume":"74","author":"Greven","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B153","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13075-016-1185-9","article-title":"Granulocyte macrophage colony-stimulating factor receptor \u03b1 expression and its targeting in antigen-induced arthritis and inflammation","volume":"18","author":"Cook","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021090119430767900_keab485-B154","doi-asserted-by":"crossref","first-page":"e20190945","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J Exp Med"},{"key":"2021090119430767900_keab485-B155","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","article-title":"MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib\/IIa randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"74","author":"Behrens","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021090119430767900_keab485-B156","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.40420","article-title":"Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor \u03b1 monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis","volume":"70","author":"Burmester","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021090119430767900_keab485-B157","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.40323","article-title":"A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021090119430767900_keab485-B158","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2665-9913(20)30170-3","article-title":"GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study","volume":"2","author":"De Luca","year":"2020","journal-title":"Lancet Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab485\/39511331\/keab485.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/3986\/40215004\/keab485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/3986\/40215004\/keab485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T17:47:55Z","timestamp":1725212875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/9\/3986\/6297401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,12]]},"references-count":158,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,12]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab485","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,12]]}}}